TRex Bio, backed by Eli Lilly and Johnson & Johnson in partnerships, priced an IPO to fund regulatory T-cell activation programs aimed at immune imbalance disorders. Separately, Retension Pharmaceuticals also launched with cash earmarked for a next-generation hypertension program, reinforcing the broader market appetite for early and mid-stage translational immunology and cardiometabolic bets.